Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Twitter
Xiaomi
Adani Group
Life Insurance Corporation of India
Stock Market
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / Business News / Female-libido enhancer Addyi's maker sold for $1 billion
Business

Female-libido enhancer Addyi's maker sold for $1 billion

Female-libido enhancer Addyi's maker sold for $1 billion
Written by Vaneet Randhawa
Aug 21, 2015, 07:26 pm 3 min read
Female-libido enhancer Addyi's maker sold for $1 billion

The Wall Street Journal reported that Valeant Pharmaceuticals International, Inc will buy Raleigh-based Sprout Pharmaceuticals for approximately $1 billion. Interestingly, this acquisition comes before the expected sale of female libido enhancer Addyi from 17 October 2015, which had been created by Sprout Pharmaceuticals. Valeant is planning to keep Sprout's leadership team unchanged and maintain its offices in Raleigh.

Introduction
Valeant's push-start to become biggest pharma company

ICN Pharmaceuticals which later became Valeant was formed as a US business by merging of several group units in the 1990s. In 2010, Valeant was born out of a merger of its U.S. predecessor and Canada's Biovail Corp. Valeant has a portfolio of more than 500 products to its name. Since its inception, Valeant has stuck to making multi-billion dollar deals aimed at expansion.

Do you know?
World famous Wellbutrin antidepressant- a Valeant product

Valeant's most famous drug is Wellbutrin, an anti-depressant and Kinerase which uses Kinetin as an ingredient and reduces freckles and spots on the skin.

29 May 2013
Bausch & Lomb acquired by Valeant

Valeant Pharmaceuticals International Inc. acquired Warburg Pincus LLC's eye-care company Bausch & Lomb Holdings Inc for $8.7 billion. Of the $8.7 billion, $4.2 billion would be used to pay Bausch & Lomb's debts. This deal is Valeant's biggest deal since its creation in 2010. With this deal, Valeant will compete in the fast growing, and highly specialized ophthalmology market.

12 May 2014
Allergan slips out of Valeant's fingers

Valeant Pharmaceuticals' $47 billion bid to take over U.S. drugmaker Allergan, mostly known as the creator of Botox failed to follow through. Valeant's business model to cut costs was not considered sustainable by Allergen who claimed that the offer was too risky. This came after Valeant's April 22 declaration saying it expected Allergan to make at least $2.7 billion in annual cost cuts.

Quote
Allergan's CEO explains why Valiant deal failed

"Valeant's model of cutting and slashing really doesn't work for more than a very short period of time," Allergan Chief Executive Officer David Pyott said.

22 Feb 2015
On to the stomach-disorders treatment market

Valeant Pharmaceuticals International Inc. divulged its plans to buy Salix Pharmaceuticals Ltd. in a $10 billion deal. The deal will make Valeant a household name for treatment of stomach disorders like traveller's diarrhoea. Valeant's deal hoped to tap the U.S. market for stomach-disorder treatments which is valued at $5 billion and is expected to grow by 5% annually.

23 Jul 2015
Valiant becomes Canada's largest company

In July 2015, Valeant Pharmaceuticals International Inc. eclipsed the Royal Bank of Canada to become Canada's largest company by market value. Valeant shares rose more than 9% to $341.02 per share (its 52 week high) and the company reached a market value of $116.3 billion on the Toronto Stock Exchange. The pharmaceutical giant has surged 105% in the current year.

Information
What is Addyi?

Addyi or what is popularly being termed as a 'female Viagra' is Sprout's latest creation, which has managed to get approval from the Food and Drugs Administration, USA but with 'severe warning'.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Vaneet Randhawa
Vaneet Randhawa
Mail
Latest
Related
Latest
Witness the power of museums this International Museum Day
Witness the power of museums this International Museum Day Lifestyle
5 anime films to watch on Amazon Prime Video
5 anime films to watch on Amazon Prime Video Entertainment
Apple releases new updates for iPhones, iPads: Details here
Apple releases new updates for iPhones, iPads: Details here Technology
IPL 2022: SRH beat MI, stay alive in playoffs race
IPL 2022: SRH beat MI, stay alive in playoffs race Sports
SC extends demolition of Noida's Supertech twin towers: Details here
SC extends demolition of Noida's Supertech twin towers: Details here Business
Related
US: Pfizer-BioNTech COVID-19 vaccine officially granted full approval by FDA
US: Pfizer-BioNTech COVID-19 vaccine officially granted full approval by FDA World
Next News Article
Next News Article

Love Business news?

Subscribe to stay updated.

Business Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022